GT719 Injection

BIOLOGICAL5 trials

Sponsors

Grit Biotechnology

Conditions

Auto Immune DiseaseAutoimmune DiseasesHematological Malignancy (Leukemia- Lymphoma)Neurological Autoimmune Diseases

Early Phase 1

GT719 Injection for Moderate to Severe Refractory Autoimmune Diseases

RecruitingNCT07122076

Grit BiotechnologyAutoimmune Diseases

Start: 2025-08-22End: 2028-08-21Target: 10Updated: 2026-09-18

A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in Adult Participants With Relapsed/Refractory CD19-positive B-cell Malignant Hematological Tumors

RecruitingNCT07131254

Grit BiotechnologyHematological Malignancy (Leukemia- Lymphoma)

Start: 2025-03-10End: 2027-12-01Target: 34Updated: 2025-12-30

GT719 Injection for Moderate to Severe Refractory Autoimmune Disease

RecruitingNCT07132112

Grit BiotechnologyAuto Immune Disease

Start: 2025-10-28End: 2028-08-01Target: 30Updated: 2026-04-16

Phase 1

GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies

RecruitingNCT06948981

Grit BiotechnologyHematological Malignancy (Leukemia- Lymphoma)

Start: 2025-04-18End: 2028-04-17Target: 46Updated: 2026-09-18

GT719 Injection for Recurrent/Refractory Antibody-mediated Neurological Immune Diseases

RecruitingNCT07021209

Grit BiotechnologyNeurological Autoimmune Diseases

Start: 2025-01-14End: 2028-01-13Target: 30Updated: 2026-09-11

Related Papers

Safety and efficacy of GT719, an off-the-shelf CAR-NKT therapy, in adults with relapsed or refractory CD19-positive B-cell malignancies.

Journal of Clinical Oncology2026-05-27

Abstract 3725: Stem cell-derived allogeneic anti-CD19 CAR-iNKT cell therapy GT719 for relapsed/refractory B cell malignancies

Cancer Research2026-04-03

First-in-human trial of GT719, a novel stem cell-derived allogeneic anti-CD19 CAR-iNKT cell therapy for relapsed/refractory B cell malignancies

Blood2025-11-03